Paus Sebastian, Schmitz-Hübsch Tanja, Wüllner Ullrich, Vogel Antje, Klockgether Thomas, Abele Michael
Department of Neurology, University of Bonn, Bonn, Germany.
Department of Ophthalmology, University of Bonn, Bonn, Germany.
Mov Disord. 2007 Jul 30;22(10):1495-1498. doi: 10.1002/mds.21542.
Several observations suggest a beneficial effect of melatonin antagonism for Parkinson's disease (PD). Although bright light therapy (BLT) suppresses melatonin release and is an established treatment for depression and sleep disturbances, it has not been evaluated in PD. We examined effects of BLT on motor symptoms, depression, and sleep in PD in a randomized placebo-controlled double-blind study in 36 PD patients, using Parkinson's Disease Rating Scale (UPDRS) I-IV, Beck's Depression Inventory, and Epworth Sleepiness Scale. All patients received BLT for 15 days in the morning, 30 min daily. Illuminance was 7.500 lux in the active treatment group and 950 lux in the placebo group. Although group differences were small, BLT led to significant improvement of tremor, UPDRS I, II, and IV, and depression in the active treatment group but not in the placebo group. It was very well tolerated. Follow up studies in more advanced patient populations employing longer treatment durations are warranted.
多项观察结果提示褪黑素拮抗作用对帕金森病（PD）具有有益效果。尽管强光疗法（BLT）可抑制褪黑素释放，且是治疗抑郁症和睡眠障碍的既定疗法，但尚未在PD患者中进行评估。我们在一项随机、安慰剂对照、双盲研究中，对36例PD患者使用帕金森病评定量表（UPDRS）I-IV、贝克抑郁量表和爱泼华嗜睡量表，研究了BLT对PD患者运动症状、抑郁和睡眠的影响。所有患者于早晨接受15天的BLT治疗，每天30分钟。活性治疗组的照度为7500勒克斯，安慰剂组为950勒克斯。尽管组间差异较小，但活性治疗组的BLT导致震颤、UPDRS I、II和IV以及抑郁有显著改善，而安慰剂组未出现。该疗法耐受性良好。有必要在更晚期患者群体中开展采用更长治疗时长的随访研究。
